Good Growth Capital’s Post

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction The Skyhawk team is delighted with the speed at which this study was conducted and thrilled to report such compelling results for SKY-0515. These topline data represent a crucial step forward for SKY-0515 and demonstrate the immense potential of the Skyhawk platform to target indications for which there are no approved disease modifying therapies. Learn More: https://lnkd.in/eYBJAnUH #HuntingtonsDisease #DrugDevelopment #Skyhawk #SmallMoleculeRNA 

Did you know... Each monoclonal antibody therapy is tailored to the unique molecular markers of a disease, ensuring that treatments are as effective as possible by directly interacting with their specific targets. #VETmAbBio #MonoclonalAntibodies #VeterinaryInnovation #PetCare #PrecisionMedicine

The first patient has been dosed in Artax Biopharma Inc’s Phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof-of-mechanism trial in #psoriasis. AX-158, a Nck blocker, acts by selectively targeting Nck function and recalibrating T-cell receptor responses. It has the broad potential to treat many #autoimmunediseases without causing immunosuppression. Safety and efficacy results from this study will be available in the second half of 2024. #autoimmune #autoimmuneawareness

This review focuses on the challenges of diagnosing and treating leptomeningeal disease (LMD), characterized by cancer cell infiltration in the leptomeningeal compartment. The complex nature of LMD and its various phenotypes can hinder effective drug delivery and treatment. Standard treatment involves intrathecal chemotherapy delivery but often leads to complications and suboptimal drug distribution. Systemic drug administration can result in off-target effects and low drug concentrations in the central nervous system. Recent advancements, such as liposomal cytarabine, have improved drug delivery for leptomeningeal metastatic disease, but more work is needed to target LMD effectively. The review discusses relevant leptomeningeal anatomy for drug penetration, conventional and advanced drug delivery methods for LMD, and future directions based on ongoing clinical trials. It emphasizes the importance of understanding LMD's complexity to develop better treatment strategies and improve patient outcomes. https://lnkd.in/dHyFVjUt #drugdelivery #leptomeningial_disease #Article_Summary

Glad to share that our project on HER2/ERBB2 dPCR has been published! Aiming to enhance precision in HER2 status determination, this work represents a critical step forward in our quest to refine diagnostic accuracy and treatment strategies for patients with HER2-driven cancers. This publication not only underscores the potential of ddPCR in clinical diagnostics but also marks a significant milestone in our ongoing efforts to improve cancer diagnostics. Stay tuned for more updates as we continue to explore new frontiers in the fight against cancer. #cancerresearch #her2 #ERBB2 #ddPCR #innovationinhealthcare #breastcancer #precisiononcology #precisionmedicine #precisiondiagnostics

HER2/ERBB2 evaluation is necessary for treatment decision-making in breast cancer (BC), however current methods have limitations and considerable variability exists. DNA copy number (CN) evaluation by droplet digital PCR (ddPCR) has complementary advantages for HER2/ERBB2 diagnostics. Multiplex ddPCR is useful for ERBB2 CN estimation and ultrahigh ERBB2 may be a predictive factor for decreased long-term survival after trastuzumab treatment. #ddPCR #Biorad #droplet #dPCR

Our journey through FDA-approved antibodies continues with Infliximab (Remicade), approved in 1998. 🔬 Antibody type: Chimeric IgG1 💊 Brand name: Remicade 🏢 Company: Janssen Biotech, Inc. 🎯 First indication: Crohn's disease Infliximab targets and neutralizes tumor necrosis factor-alpha (TNF-α), a cytokine involved in systemic inflammation. By inhibiting TNF-α, Infliximab reduces inflammation and alleviates symptoms in autoimmune diseases such as Crohn's disease. Stay tuned for more insights on FDA-approved antibodies next week! #AntibodyOfTheWeek #FDAApproved #MonoclonalAntibodies #AutoimmuneDisease #Inflammation #Biotechnology #MedicalInnovation

🎊 Celebrating a Liver Disease Breakthrough! 🎊 Chemomab Therapeutics has just hit a major milestone in the fight against liver fibrosis! 🎉 Their novel drug candidate, CM-101, showed promising results in a Phase 2a trial for non-alcoholic steatohepatitis (NASH) patients. Let’s dive into the details: 🔍 Key Findings: - CM-101 met its primary endpoint of safety and tolerability. - Patients receiving CM-101 demonstrated improvements in multiple liver fibrosis biomarkers. - Notably, almost 60% of CM-101-treated patients responded positively in at least three biomarkers at week 20. 💉 Why It Matters: - CM-101’s anti-inflammatory and anti-fibrotic activity holds immense promise. - This success builds on similar data from other trials, including non-alcoholic fatty liver disease (NAFLD) and acute lung injury in COVID patients. 📈 Despite investor retreat, Chemomab remains committed to advancing research in primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). #ClinicalData #Contractresearch #Wallstreet #Liverdisease #CM101 #ClinicalResearch

Expand your knowledge of #complement modulation therapeutics by clicking the link below.

Viridian Therapeutics announced positive topline data from its phase 3 THRIVE clinical trial (NCT05176639) of veligrotug, previously known as VRDN-001, in patients with active thyroid eye disease (TED). Results showed that patients who received veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, had “statistically significant and clinically meaningful improvements across [multiple] key disease endpoints at the primary efficacy analysis timepoint of 15 weeks.” Furthermore, THRIVE met both the primary and all secondary endpoints at 15 weeks after 5 infusions of veligrotug. Additionally, veligrotug showed a rapid onset of action, with the majority (53%) of veligrotug-treated patients achieving a proptosis response after just 1 infusion, or 3 weeks after the start of therapy. Read more: https://lnkd.in/e6j5AZih